ProBioGen, Surface Oncology Sign Agreement

ProBioGen AG has signed a second antibody development project with Surface Oncology Inc., an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.

Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate. 

“We have worked together with Surface Oncology very well for quite a while and this is now our second potential clinical antibody project together,” said Gabriele Schneider, chief business officer, ProBioGen. “We have established a seamless team working across our companies and we are very pleased to continue to expand this relationship with Surface Oncology”.